Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study
Open Access
- 30 July 2013
- journal article
- research article
- Published by Hindawi Limited in ISRN Hematology
- Vol. 2013, 1-9
- https://doi.org/10.1155/2013/908191
Abstract
The aim of this single-center, retrospective study was to investigate the impact of rituximab, reconsider the validity of International Prognostic Index (IPI), and evaluate the prognostic role of the cell of origin (CoO) in a relatively young cohort. Three hundred twelve diffuse large B cell lymphoma patients (median age: 52) were included. Rituximab significantly improved the 3- and 5-year progression free survival (PFS) (70% versus 65% and 41% versus 36%, resp.; ) but led only to a slight, insignificant increase in 3- and 5-year overall survival (OS) (71% versus 77.3% and %67 versus 74.5%, resp.; ). In the young, low risk patient subgroup (aaIPI = 0&1; ), rituximab improved 3- and 5-year PFS and OS rates ( and , resp.). The efficacy of rituximab in young high risk patients was comparable to the literature. CoO data were available in 190 patients. The OS at 3 years was 79% for GC and 64% for non-GC subgroups (). To the best of our knowledge, this is the first study which investigated the impact of R-CHOP in the context of CoO and IPI in a relatively young cohort. CoO was not an independent risk factor for prognosis in the multivariate analysis although patients with GC showed a significant survival advantage in the univariate analysis. CoO was also found to be a significant determinant of response in refractory/relapsed patients. Our results confirm the efficacy of rituximab in low and high risk, young patients outside of a randomized clinical trial setting.
Keywords
Funding Information
- Istanbul Üniversitesi (404/03062005)
This publication has 30 references indexed in Scilit:
- Predicting survival for diffuse large B‐cell lymphoma patients using baseline neutrophil/lymphocyte ratioAmerican Journal of Hematology, 2010
- Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending storyAnnals of Oncology, 2010
- High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphomaAnnals of Oncology, 2010
- Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell LymphomaThe Korean Journal of Internal Medicine, 2010
- Prognostic impact of immunohistochemical biomarkers in diffuse large B‐cell lymphoma in the rituximab eraCancer Science, 2009
- Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter studyHaematologica, 2009
- Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapyAnnals of Oncology, 2007
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Blood, 2003
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000